The federal Project Grant award of $300,000.00 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the development of novel immunotherapeutic molecules against the sexually transmitted infection gonorrhea. The award is funding research by Planet Biotechnology Incorporated, a biotechnology company specializing in engineered fusion proteins that combine human antibody elements with other immune system components. The key goals are to create Factor H-Fc and C4BP-Fc fusion proteins that are effective against both predominant strains of the Neisseria gonorrhoeae bacteria, with the aim of developing a combination immunotherapeutic treatment that provides broad protection. The research involves designing, producing, and evaluating the efficacy of these fusion proteins in vitro and in animal models, to identify lead candidates for further preclinical development. This federal award supports Planet Biotechnology's ongoing efforts to pioneer novel approaches to combating challenging infectious diseases through innovative immunotherapeutic strategies.
Generated 2/25/25, 5:37 AM